208 related articles for article (PubMed ID: 32865454)
1. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.
Allan R; Canham K; Wallace R; Singh D; Ward J; Cooper A; Newcomb C
J Aerosol Med Pulm Drug Deliv; 2021 Apr; 34(2):134-145. PubMed ID: 32865454
[No Abstract] [Full Text] [Related]
2.
Shepherd T; Kennett M; Cooper A; Parkinson A
J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):154-165. PubMed ID: 34726509
[No Abstract] [Full Text] [Related]
3. Wixela Inhub: Dosing Performance
Cooper A; Parker J; Berry M; Wallace R; Ward J; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788
[No Abstract] [Full Text] [Related]
4. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
Ng D; Kerwin EM; White MV; Miller SD; Haughie S; Ward JK; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):99-107. PubMed ID: 31634023
[No Abstract] [Full Text] [Related]
5. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Feldman WB; Kesselheim AS; Avorn J; Russo M; Wang SV
Ann Intern Med; 2023 Aug; 176(8):1047-1056. PubMed ID: 37549393
[TBL] [Abstract][Full Text] [Related]
6. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
Haughie S; Allan R; Wood N; Ward J
J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
8. Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD.
Donohue JF; Burgoyne DS; Ward JK; Allan R; Koltun A; Cooper A
Pulm Ther; 2021 Jun; 7(1):47-57. PubMed ID: 33284384
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[TBL] [Abstract][Full Text] [Related]
10. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
Tashkin DP; Ohar JA; Koltun A; Allan R; Ward JK
Pulm Med; 2021; 2021():8881895. PubMed ID: 33815843
[TBL] [Abstract][Full Text] [Related]
11. A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness.
Tashkin DP; Koltun A; Wallace R
Allergy Asthma Proc; 2021 Jan; 42(1):30-35. PubMed ID: 33353582
[No Abstract] [Full Text] [Related]
12. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
Aubier M; Pieters WR; Schlösser NJ; Steinmetz KO
Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
Vutikullird AB; Gillespie M; Song S; Steinfeld J
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
[TBL] [Abstract][Full Text] [Related]
14. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
[TBL] [Abstract][Full Text] [Related]
16. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
Bateman ED; Silins V; Bogolubov M
Respir Med; 2001 Feb; 95(2):136-46. PubMed ID: 11217910
[TBL] [Abstract][Full Text] [Related]
17. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
Kavuru M; Melamed J; Gross G; Laforce C; House K; Prillaman B; Baitinger L; Woodring A; Shah T
J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1108-16. PubMed ID: 10856143
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
Li S; Feng K; Lee J; Gong Y; Wu F; Newman B; Yoon M; Fang L; Zhao L; Gobburu JVS
AAPS J; 2024 Apr; 26(3):56. PubMed ID: 38671158
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
Nugent C; Yiu G; Song S; Caracta C
J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
